RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or
bacterial infection and induce host innate immune responses. The RLRs family comprises …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective
therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in …

Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

C-type lectin-like molecule-1 (CLL1) is preferentially expressed on acute myeloid leukemia
(AML) stem cells and AML blasts, which can be considered as AML-associated antigen. Anti …

Simple Summary Acute myeloid leukemia (AML) is an aggressive cancer of stem cells
originating in the bone marrow. Increasing evidence suggests that AML survival and relapse …

Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …

Backgrounds Chimeric antigen receptor (CAR)-T cell therapy has achieved unprecedented
success in treating hematopoietic malignancies. However, this cell therapy is hampered in …

Advanced Therapy Medicinal Products (ATMPs) based on somatic cells expanded in vitro,
with or without genetic modification, is a rapidly growing area of drug development, even …